AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Cytochrome P450 2A13

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q16696

UPID:

CP2AD_HUMAN

Alternative names:

CYPIIA13

Alternative UPACC:

Q16696; Q53YR8; Q6R569; Q6R570; Q9H2X2

Background:

Cytochrome P450 2A13 (CYPIIA13), encoded by the gene with accession number Q16696, plays a crucial role in the metabolism of various substances, including carcinogens found in tobacco. It exhibits activities such as coumarin 7-hydroxylase and is active in the metabolic activation of compounds like hexamethylphosphoramide and N-nitrosomethylphenylamine, highlighting its significant role in biochemical pathways.

Therapeutic significance:

Understanding the role of Cytochrome P450 2A13 could open doors to potential therapeutic strategies. Its involvement in the metabolism of carcinogenic substances makes it a target of interest for developing interventions aimed at preventing or treating diseases related to tobacco exposure.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.